Navigation Links
Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Date:10/28/2008

OSLO, October 28 /PRNewswire-FirstCall/ -- DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services With this laboratory service and following CE marking scheduled in early2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression diagnostic test for early detection of breast cancer and Alzheimer's disease in a CLIA/ISO17025 certified environment.

"This agreement with DNAVision will provide us with the ideal launch platform across Europe for our blood-based tests for early detection of breast cancer and Alzheimer's disease," said DiaGenic CEO Erik Christensen, M.D., Ph.D., "We are currently introducing the breast cancer test in India. The key advantages of our tests are the ease of sample collection and the ability to detect the earliest signs of disease. However, quality control is equally important in generating provider and patient confidence. We therefore regard DNAVision as an ideal partner since their testing facilities for molecular diagnostics comply with the most advanced quality standards in Europe."

"We are delighted to provide the diagnostic testing arm for DiaGenic in Europe for their breast cancer and Alzheimer's disease tests. We are convinced that such tests are laying the basis for new levels of diagnostic services that will benefit overall healthcare provision in Europe " said Jean-Pol Detiffe, CEO of DNAVision. "This agreement is also continuing confirmation that DNAVision has become the partner of choice for biotech companies who want to step into the diagnostic market without facing long IVD application procedures, but with the help of a quality certified service provider generating data available for clinical and diagnostic purposes."

"In parallel to this agreement, we are finalizing marketing in preparation for a full Egy" timex="10/28/2008 11:36:55 AM" dirsub="( OSLO October 28 /- DiaGenic ASA (...)" id="8666" index="biology" dir="Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests" dir2="Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression B..." keywords1=",biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology" keywords="Diagenic,Partners,With,DNAVision,to,Offer,First,Breast,Cancer,and,Alzheimers,Gene-Expression,Blood,Tests" description="... OSLO October 28 /- DiaGenic ASA (OSL:DIAG)... This agreement with DNAVision will provide us with the ideal launchp... We are delighted to provide the diagnostic testing arm for DiaGenic i... In parallel to this agreement we are finalizing marketing inprepara..." url=u&"/biology-technology-1/Diagenic-Partners-With-DNAVision-to-Offer-First-Breast-Cancer-and-Alzheimers-Gene-Expression-Blood-Tests-8666-2/" title="Diagenic%20Partners%20With%20DNAVision%20to%20Offer%20First%20Breast%20Cancer%20and%20Alzheimers%20Gene-Expression%20Blood%20Tests" %> Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression B... ( OSLO October 28 /- DiaGenic ASA (...)

Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Date:10/28/2008

uropean launch early next year following CE marking of both the breast cancer and Alzheimer's test," concluded Dr Christensen.

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit http://www.diagenic.com

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services.

DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision's service portfolio can be found on http://www.dnavision.com

Corporate Inquiries: Erik Christensen, Managing Director DiaGenic ASA, Grenseveien 92, NO-0663 Oslo, Norway, Tel +47-95939918, Email: erik.christensen@diagenic.com; Media Inquiries: For DNAVision: Michael Herman, DNAVision, Tel +32-71378527, Email m.herman@dnavision.com


'/>"/>
SOURCE DiaGenic ASA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive small business ... had the goal of bringing their powerful cuvette and spectrophotometer calibration to ... that FireflySci is going on as they add yet another mark on the global ...
(Date:2/23/2017)... YORK , Feb. 23, 2017 ... digital health company, and Digital Noema Telehealth ... remote patient monitoring, announce they are partnering to ... DN Telehealth maximizes collaboration compatibility for its ... beyond a physical clinical setting to include fully ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
Breaking Biology Technology:
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):